“The launch of Leqembi signifies a pivotal shift in the battle against Alzheimer’s and related dementia disorders. This marks the introduction of the first clinically relevant disease-modifying drug for Alzheimer’s disease. Be Well Memory and Infusion is at the forefront of adopting these groundbreaking therapies, driven by the unparalleled expertise of our clinical team.”
Infusion
Be Well Memory and Infusion is a unique clinical practice which focuses on treating individuals with cognitive decline. We offer comprehensive care for patients and families dealing with dementia. Our clinic is among the first to offer the FDA-approved Alzheimer’s treatment called lecanemab or known by its brand name, Leqembi ™.
Leqembi has been shown to slow the cognitive and functional decline in early stages of the disease. Individuals with mild cognitive impairment or mild-stage dementia due to Alzheimer’s disease are eligible to receive Leqembi.
The service is managed by fellowship-trained medical experts including a Be Well geriatrician and neurologist, with a combined xx years of experience in dealing with cognitive decline in older adults.
Schedule an appointment to learn if you or your loved one is eligible for Leqembi.
Commonly asked questions about Leqembi:
How is Leqembi administered?
The drug is given as an intravenous infusion once every two weeks. Each infusion takes about an hour.
How much does Leqembi cost?
Eisai, the drug’s manufacturer, has set a yearly price of $26,500.
The Centers for Medicare and Medicaid Services (CMS) and insurance companies are in the process of determining coverage.
How do I know if I can be treated with Leqembi?
Tests are administered to determine eligibility. These tests can be completed in our center.
A history and assessment of cognition and day to day function.
MRI scan of the brain to look for evidence of small areas of blood in the brain. These are called micro-hemorrhages. They are common in persons with Alzheimer’s Disease and may increase risks by taking Leqembi.
Blood work helps to determine if there are other causes of cognitive impairments other than Alzheimer’s Disease.
Genetic testing to test for a gene called APOE which may increase your risks from the treatment.
A PET scan to test for the presence of beta-amyloid in the brain.